About Murren Biotechnology
Murren Biotechnology is a Healthcare company based in Beijing (China) founded in 2015 by Jiang Xianzhi. Microbial separation and cultivation technologies are developed for various applications. Murren Biotechnology has raised $50.6 million across 3 funding rounds from investors including SDIC, Yuexiu Capital and Highlight Capital. Its chief executive, as recorded, is Jiang Xianzhi. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Murren Biotechnology was founded in 2015 in Beijing, China, within the biotechnology sector. Microbial separation and cultivation technologies are developed, including Eco-screening TM for screening processes, fungal high-density solid fermentation technology that controls oxygen, water, pH, carbon, and nitrogen sources, and microfilm coating technology applied to seed surfaces to prevent microbial damage. These technologies support operations in biological agriculture, human microbiome research for biomedicine, and gene discovery.
- Headquarters Beijing, China
- Founders Jiang Xianzhi
- SectorsHealthcare
- Phone•••• ••••
- Website moonbio.com
- Total Equity Funding$50.6M (USD)
in 3 rounds
- Latest Funding Round$41.27M (USD), Series C
Jul 2024
- InvestorsSDIC
& 2 more
Funding Insights of Murren Biotechnology
Murren Biotechnology has successfully raised a total of $50.6M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $41.27 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50.6M
- Total Rounds 3
- Last Round Series C — $41.27M
- First Round $9.33M
(Jun 2018)
- Investors Count 3
All 3 funding rounds of Murren Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $41.27M | Series C | – | SDIC | – |
| Feb 2020 | Series B | – | Guangzhou Yuexiu Industrial Investment Fund Management | – | |
| Jun 2018 | $9.33M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Murren Biotechnology
Murren Biotechnology has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include SDIC, Yuexiu Capital and Highlight Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Yuexiu Capital is engaged in financial services and asset management. | yuexiufund.com | Guangzhou, China | ||
Private equity and early-stage venture capital firm investing primarily in Chinese companies | highlightcapital.com | Shanghai, China | ||
Investment holding company | 1995 | sdic.com.cn | Beijing, China |
Investor details for Murren Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Murren Biotechnology
4 people are tracked at Murren Biotechnology (4 in leadership).
| Name | Role | Group |
|---|---|---|
Jiang Xianzhi | Founder & CEO | Leadership |
先芝 蒋 | Founder & CEO | Leadership |
Zhao Chang | Director Of Public Relations | Leadership |
Chuan-Sheng Lin | Chief Scientific Officer | Leadership |
Complete people profiles for Murren Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Murren Biotechnology
3 dated milestones of Murren Biotechnology across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Murren Biotechnology is founded.
- Funding First funding round of $9.3M.
- Funding Latest funding round, Series C, of $41.3M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Murren Biotechnology
Murren Biotechnology was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Murren Biotechnology is headquartered in Beijing, China.
Jiang Xianzhi is the CEO of Murren Biotechnology, as recorded in our data. They have also founded this company.
Murren Biotechnology is a funded company, having raised a total of $50.6M across 3 funding rounds to date. The company's 1st funding round was a Seed of $9.33M, raised on Jun 2018.
Murren Biotechnology was founded in 2015 in Beijing, China, within the biotechnology sector. Microbial separation and cultivation technologies are developed, including Eco-screening TM for screening processes, fungal high-density solid fermentation technology that controls oxygen, water, pH, carbon, and nitrogen sources, and microfilm coating technology applied to seed surfaces to prevent microbial damage. These technologies support operations in biological agriculture, human microbiome research for biomedicine, and gene discovery.
Murren Biotechnology has 3 investors. Key investors include SDIC, Yuexiu Capital, and Highlight Capital.